Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

180.96 +2.38 (+1.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories Intl

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Expert Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Recap: Charles River Q2 Earnings
  Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Charles River Laboratories Expands Contract Vivarium Space on West Coast
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River: Q1 Earnings Insights
Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
From Charles River Laboratories, International Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
Upgrades 
Via Benzinga
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL). 
Via Benzinga
Where Charles River Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces First-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
Preview: Charles River's Earnings
Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River... 
Via Benzinga
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
From Charles River Laboratories International, Inc.
Via Business Wire
3 Top S&P 500 Stock Market Gainers Today: Coronavirus Vaccine Maker Moderna Jumps
Moderna led big-cap winners Monday. Oil services giants were losers. 
Via Investor's Business Daily
Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know
Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Charles River
Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.